Novel perfluoroketone compounds of formula [I] and [Ia] are described. Also described are uses thereof, such as for inhibition of phospholipase A
2
activity. Therapeutic uses thereof are also described, such as for the treatment of neural conditions and/or inflammatory conditions, such as demyelinating (e.g., multiple sclerosis) and neural injury (e.g., spinal cord injury).
[EN] PERFLUOROKETONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE PERFLUOROCÉTONE ET LEURS UTILISATIONS
申请人:UNIV MCGILL
公开号:WO2008122119A1
公开(公告)日:2008-10-16
[EN] Novel perfluoroketone compounds of formula [I] and [Ia] are described Also described are uses thereof, such as for inhibition of phospholipase A2 activity. Therapeutic uses thereof are also described, such as for the treatment of neural conditions and / or inflammatory conditions, such as demeyelmatmg (e.g., multiple sclerosis) and neural injury (e.g., spinal cord injury). [FR] L'invention concerne de nouveaux composés de perfluorocétone. Elle concerne également leurs utilisations, par exemple, pour inhiber l'activité de phospholipase A2. Elle concerne également leurs utilisations thérapeutiques, par exemple, pour traiter des états neuraux et/ou inflammatoires, tels que la démyélinisation (par exemple, la sclérose en plaques) et la lésion neurale (par exemple, la lésion de la moëlle épinière).
Potent and Selective Fluoroketone Inhibitors of Group VIA Calcium-Independent Phospholipase A<sub>2</sub>
作者:George Kokotos、Yuan-Hao Hsu、John E. Burke、Constantinos Baskakis、Christoforos G. Kokotos、Victoria Magrioti、Edward A. Dennis
DOI:10.1021/jm901872v
日期:2010.5.13
Group VIA calcium-independent phospholipase A2 (GVIA iPLA2) has recently emerged as a novel pharmaceutical target. We have now explored the structure−activity relationship between fluoroketones and GVIA iPLA2 inhibition. The presence of a naphthyl group proved to be of paramount importance. 1,1,1-Trifluoro-6-(naphthalen-2-yl)hexan-2-one (FKGK18) is the most potent inhibitor of GVIA iPLA2 (XI(50) =
VIA 组钙非依赖性磷脂酶 A 2 (GVIA iPLA 2 ) 最近已成为一种新的药物靶点。我们现在已经探索了氟酮和 GVIA iPLA 2抑制之间的构效关系。萘基的存在被证明是极其重要的。1,1,1-Trifluoro-6-(naphthalen-2-yl)hexan-2-one (FKGK18) 是迄今为止报道的最有效的 GVIA iPLA 2抑制剂( X I (50) = 0.0002)。GVIA iPLA 2的效力分别是 GIVA cPLA 2和 GV sPLA 2 的195 倍和 >455 倍,使其成为探索 GVIA iPLA 2作用的宝贵工具在细胞和体内模型中。1,1,1,2,2,3,3-Heptafluoro-8-(naphthalene-2-yl)octan-4-one 抑制 GVIA iPLA 2,X I (50) 值为 0.001,同时抑制其他细胞内 GIVA cPLA
A Convergent, Modular Approach to Trifluoromethyl‐Bearing 5‐Membered Rings via Catalytic C(sp
<sup>3</sup>
)−H Activation
作者:Kai Wu、Xuyang Zhang、Liang‐Liang Wu、Jie‐Sheng Huang、Chi‐Ming Che
DOI:10.1002/anie.202215891
日期:2023.2.20
modular approach to access CF3-bearing 5-membered carbo- and heterocycles via catalytic C (sp3)−H insertion is demonstrated. In the case of carbocycles, an asymmetric benzylic C−H insertion process allowed to reach high regio-, diastereo- and enantioselectivities. This protocol can be applied to the synthesis of chiral CF3 analogues of medicinal agents and natural products. The origin of selectivity